Global Pulmonary Alveolar Proteinosis (PAP) Market: Industry Analysis & Outlook (2017-2025)
Pulmonary alveolar proteinosis (PAP) is a rare respiratory disease caused by the accumulation of a surfactant (proteins and lipids) accumulated in small air bags of the lung, called alveoli, which interfere with breathing. PAP condition occurs in 6 individuals per million and is considered an orphan disease.
Pulmonary surfactant is produced by the body in healthy people and patients with PAP, which is a mixture of phospholipids and synthesized proteins. These surfactants form cell lines to prevent the collapse of the pulmonary membranes by reducing the surface tension. This pulmonary surfactant must be constantly replaced to maintain the active and functional layer and to prevent excessive layering. The exact reason for the accumulation of excess surfactants is unknown. This requires a signal and messenger molecule called granulocyte-macrophage colony stimulating factor (GM-CSF) to stimulate alveolar macrophages to work properly and maintain a normal level of surfactant in the cells. This process of maintaining a stable state is known as homeostasis and requires that GM-CSF stimulate alveolar macrophages to remove excess surfactant.
Treatment of PAP depends on the form of PAP and age of a patient with PAP and severity of the disease. WLL is a standard treatment for PAP and the only treatment which has shown improved symptoms and oxygenation in patients. Another treatment of PAP includes using recombinant granulocyte colony stimulating factor (GM-CSF) which is given by nose or with a subcutaneous injection which is not approved yet.
The global PAP market is expected to show significant growth after the introduction of the molgradex drug in 2020. The growth of market will mainly be driven by huge unmet demand, increasing male population, rising middle-aged population and increasing health expenditure. However, the growth of the market will be hindered by the absence of effective diagnostics and costly drugs.
The report “Global Pulmonary Alveolar Proteinosis (PAP) Market: Industry Analysis & Outlook (2017-2025)” analyzes the development of this market, with focus on the US, Europe, and Japan region. The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. A key upcoming player in the market i.e. Savara Inc. is being profiled along with its key financials and strategies for growth. The report contains a comprehensive analysis of the global PAP market along with the study of the regional markets.
Pulmonary surfactant is produced by the body in healthy people and patients with PAP, which is a mixture of phospholipids and synthesized proteins. These surfactants form cell lines to prevent the collapse of the pulmonary membranes by reducing the surface tension. This pulmonary surfactant must be constantly replaced to maintain the active and functional layer and to prevent excessive layering. The exact reason for the accumulation of excess surfactants is unknown. This requires a signal and messenger molecule called granulocyte-macrophage colony stimulating factor (GM-CSF) to stimulate alveolar macrophages to work properly and maintain a normal level of surfactant in the cells. This process of maintaining a stable state is known as homeostasis and requires that GM-CSF stimulate alveolar macrophages to remove excess surfactant.
Treatment of PAP depends on the form of PAP and age of a patient with PAP and severity of the disease. WLL is a standard treatment for PAP and the only treatment which has shown improved symptoms and oxygenation in patients. Another treatment of PAP includes using recombinant granulocyte colony stimulating factor (GM-CSF) which is given by nose or with a subcutaneous injection which is not approved yet.
The global PAP market is expected to show significant growth after the introduction of the molgradex drug in 2020. The growth of market will mainly be driven by huge unmet demand, increasing male population, rising middle-aged population and increasing health expenditure. However, the growth of the market will be hindered by the absence of effective diagnostics and costly drugs.
The report “Global Pulmonary Alveolar Proteinosis (PAP) Market: Industry Analysis & Outlook (2017-2025)” analyzes the development of this market, with focus on the US, Europe, and Japan region. The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. A key upcoming player in the market i.e. Savara Inc. is being profiled along with its key financials and strategies for growth. The report contains a comprehensive analysis of the global PAP market along with the study of the regional markets.
1. MARKET OVERVIEW
1.1 Pulmonary Alveolar Proteinosis (PAP)
1.2 Types of PAP
1.3 Symptoms & Causes
1.4 Diagnosis
1.5 Treatment
2. GLOBAL PAP MARKET
2.1 Global PAP Market
2.1.1 Global PAP Patient Prevalence Forecast
2.1.2 Global PAP Prevalence by Type
2.1.3 Global PAP Prevalence Forecast by Region
2.2 Global PAP Market by Drug
2.2.1 Global Molgradex Addressable Population Forecast
2.2.2 Global Patients on Molgradex Therapy Forecast
2.2.3 Global Molgradex Revenue Forecast
3. REGIONAL MARKET ANALYSIS
3.1 The US
3.1.1 The US PAP Patient Prevalence Forecast
3.1.2 The US Molgradex Addressable Population Forecast
3.1.3 The US Patient on Molgradex Therapy Forecast
3.1.4 The US Molgradex Revenue Forecast
3.2 Europe
3.2.1 Europe PAP Patient Prevalence Forecast
3.2.2 Europe Molgradex Addressable Population Forecast
3.2.3 Europe Patient on Molgradex Therapy Forecast
3.2.4 Europe Molgradex Revenue Forecast
3.3 Japan
3.3.1 Japan PAP Patient Prevalence Forecast
3.3.2 Japan Molgradex Addressable Population Forecast
3.3.3 Japan Patient on Molgradex Therapy Forecast
3.3.4 Japan Molgradex Revenue Forecast
4. MARKET DYNAMICS
4.1 Growth Drivers
4.1.1 Improving Global Economy
4.1.2 Rising Healthcare Spending
4.1.3 Rising Middle-Aged Population
4.1.4 Increasing Male Population
4.1.5 Huge Unmet Demand
4.2 Key Trends & Developments
4.2.1 Mergers and Acquisitions
4.2.2 Orphan Drug Designation
4.2.3 Increasing Awareness
4.2.4 Favorable Reimbursement Landscape
4.2.5 Limited Competition
4.3 Challenges
4.3.1 Expensive Alternative Procedures
4.3.2 Absence of Low-Priced and Effective Diagnostics
5. COMPETITIVE LANDSCAPE
5.1 Global Market
5.1.1 Global WLL Treatment Forecast
5.2 The US
5.2.1 The US WLL Treatment Forecast
5.3 Europe
5.3.1 Europe WLL Treatment Forecast
5.4 Japan
5.4.1 Japan WLL Treatment Forecast
6. COMPANY PROFILES
6.1 Savara Inc.
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
1.1 Pulmonary Alveolar Proteinosis (PAP)
1.2 Types of PAP
1.3 Symptoms & Causes
1.4 Diagnosis
1.5 Treatment
2. GLOBAL PAP MARKET
2.1 Global PAP Market
2.1.1 Global PAP Patient Prevalence Forecast
2.1.2 Global PAP Prevalence by Type
2.1.3 Global PAP Prevalence Forecast by Region
2.2 Global PAP Market by Drug
2.2.1 Global Molgradex Addressable Population Forecast
2.2.2 Global Patients on Molgradex Therapy Forecast
2.2.3 Global Molgradex Revenue Forecast
3. REGIONAL MARKET ANALYSIS
3.1 The US
3.1.1 The US PAP Patient Prevalence Forecast
3.1.2 The US Molgradex Addressable Population Forecast
3.1.3 The US Patient on Molgradex Therapy Forecast
3.1.4 The US Molgradex Revenue Forecast
3.2 Europe
3.2.1 Europe PAP Patient Prevalence Forecast
3.2.2 Europe Molgradex Addressable Population Forecast
3.2.3 Europe Patient on Molgradex Therapy Forecast
3.2.4 Europe Molgradex Revenue Forecast
3.3 Japan
3.3.1 Japan PAP Patient Prevalence Forecast
3.3.2 Japan Molgradex Addressable Population Forecast
3.3.3 Japan Patient on Molgradex Therapy Forecast
3.3.4 Japan Molgradex Revenue Forecast
4. MARKET DYNAMICS
4.1 Growth Drivers
4.1.1 Improving Global Economy
4.1.2 Rising Healthcare Spending
4.1.3 Rising Middle-Aged Population
4.1.4 Increasing Male Population
4.1.5 Huge Unmet Demand
4.2 Key Trends & Developments
4.2.1 Mergers and Acquisitions
4.2.2 Orphan Drug Designation
4.2.3 Increasing Awareness
4.2.4 Favorable Reimbursement Landscape
4.2.5 Limited Competition
4.3 Challenges
4.3.1 Expensive Alternative Procedures
4.3.2 Absence of Low-Priced and Effective Diagnostics
5. COMPETITIVE LANDSCAPE
5.1 Global Market
5.1.1 Global WLL Treatment Forecast
5.2 The US
5.2.1 The US WLL Treatment Forecast
5.3 Europe
5.3.1 Europe WLL Treatment Forecast
5.4 Japan
5.4.1 Japan WLL Treatment Forecast
6. COMPANY PROFILES
6.1 Savara Inc.
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
LIST OF FIGURES
Types of PAP (Pulmonary Alveolar Proteinosis)
Diagnosis of PAP (Pulmonary Alveolar Proteinosis)
Treatment of PAP (Pulmonary Alveolar Proteinosis)
Global PAP Patient Prevalence Forecast (2017-2025)
Global PAP Prevalence by Type (2016)
Global PAP Prevalence Forecast by Region (2020)
Global Molgradex Addressable Population Forecast (2017-2025)
Global Patients on Molgradex Therapy Forecast (2020-2025)
Global Molgradex Revenue Forecast (2020-2025)
The US PAP Patient Prevalence Forecast (2017-2025)
The US Molgradex Addressable Population Forecast (2017-2025)
The US Patient on Molgradex Therapy Forecast (2020-2025)
The US Molgradex Revenue Forecast (2020-2025)
Europe PAP Patient Prevalence Forecast (2017-2025)
Europe Molgradex Addressable Population Forecast (2017-2025)
Europe Patient on Molgradex Therapy Forecast (2020-2025)
Europe Molgradex Revenue Forecast (2020-2025)
Japan PAP Patient Prevalence Forecast (2017-2025)
Japan Molgradex Addressable Population Forecast (2017-2025)
Japan Patient on Molgradex Therapy Forecast (2020-2025)
Japan Molgradex Revenue Forecast (2020-2025)
Global GDP per Capita (2012-2016)
Global Healthcare Spending Per Capita (2012-2016)
Global Middle-Aged Population (2012-2016)
Global Male Population (2012-2016)
Global WLL Treatment Forecast (2016-2025)
The US WLL Treatment Forecast (2016-2025)
Europe WLL Treatment Forecast (2016-2025)
Japan WLL Treatment Forecast (2016-2025)
Savara Inc. Revenue and Net Loss (2012-2016)
Savara Inc. Estimated Revenue (2020-2025)
Savara Inc. Research & Development Expenses (2014-2016)
Types of PAP (Pulmonary Alveolar Proteinosis)
Diagnosis of PAP (Pulmonary Alveolar Proteinosis)
Treatment of PAP (Pulmonary Alveolar Proteinosis)
Global PAP Patient Prevalence Forecast (2017-2025)
Global PAP Prevalence by Type (2016)
Global PAP Prevalence Forecast by Region (2020)
Global Molgradex Addressable Population Forecast (2017-2025)
Global Patients on Molgradex Therapy Forecast (2020-2025)
Global Molgradex Revenue Forecast (2020-2025)
The US PAP Patient Prevalence Forecast (2017-2025)
The US Molgradex Addressable Population Forecast (2017-2025)
The US Patient on Molgradex Therapy Forecast (2020-2025)
The US Molgradex Revenue Forecast (2020-2025)
Europe PAP Patient Prevalence Forecast (2017-2025)
Europe Molgradex Addressable Population Forecast (2017-2025)
Europe Patient on Molgradex Therapy Forecast (2020-2025)
Europe Molgradex Revenue Forecast (2020-2025)
Japan PAP Patient Prevalence Forecast (2017-2025)
Japan Molgradex Addressable Population Forecast (2017-2025)
Japan Patient on Molgradex Therapy Forecast (2020-2025)
Japan Molgradex Revenue Forecast (2020-2025)
Global GDP per Capita (2012-2016)
Global Healthcare Spending Per Capita (2012-2016)
Global Middle-Aged Population (2012-2016)
Global Male Population (2012-2016)
Global WLL Treatment Forecast (2016-2025)
The US WLL Treatment Forecast (2016-2025)
Europe WLL Treatment Forecast (2016-2025)
Japan WLL Treatment Forecast (2016-2025)
Savara Inc. Revenue and Net Loss (2012-2016)
Savara Inc. Estimated Revenue (2020-2025)
Savara Inc. Research & Development Expenses (2014-2016)
LIST OF TABLES
Mergers and Acquisitions (2016-2017)
Savara Inc. Products Under Pipeline (2016)
Molgradex Clinical Study For aPAP (2016)
IMPALA Trial Endpoints
Mergers and Acquisitions (2016-2017)
Savara Inc. Products Under Pipeline (2016)
Molgradex Clinical Study For aPAP (2016)
IMPALA Trial Endpoints
